The present disclosure belongs to polymercaptan compounds and application fields thereof, and particularly relates to a polymercaptan compound and a preparation method thereof, a curing agent, a resin composition, an adhesive and a sealant. The polymercaptan compound is represented by formula (I), wherein R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.7 and R.sup.8 are each independently selected from one of a hydrogen atom, an alkyl group with 1-5 carbon atoms and an alkoxy group with 1-5 carbon atoms, R.sup.4 and R.sup.6 are each independently selected from an alkylene group with 1-5 carbon atoms, and m and n are each independently 0, 1, 2 or 3.

Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein. The present compounds are activators of PPAR and may be useful for treating conditions mediated by the same.

Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein. The present compounds are activators of PPAR and may be useful for treating conditions mediated by the same.

Using a combination of Kumada, Suzuki and Biellmann chemistry, various menaquinones can synthesized rapidly and with stereochemical integrity offering a new way of preparing these vitamin K2 components for the pharmaceutical market. In one embodiment a process for the preparation of a compound of formula (I) ##STR00001## is defined including a step in which (i) a compound of formula (II) is reacted with a compound of formula (III) ##STR00002## wherein R is an alkyl group; LG is a leaving group; m is an integer from 0 to 8; n is an integer of from 0 to 9; and X is hydrogen, halide, hydroxyl or protected hydroxyl; in the presence of a copper, nickel or palladium catalyst.

Using a combination of Kumada, Suzuki and Biellmann chemistry, various menaquinones can synthesized rapidly and with stereochemical integrity offering a new way of preparing these vitamin K2 components for the pharmaceutical market. In one embodiment a process for the preparation of a compound of formula (I) ##STR00001## is defined including a step in which (i) a compound of formula (II) is reacted with a compound of formula (III) ##STR00002## wherein R is an alkyl group; LG is a leaving group; m is an integer from 0 to 8; n is an integer of from 0 to 9; and X is hydrogen, halide, hydroxyl or protected hydroxyl; in the presence of a copper, nickel or palladium catalyst.

Provided is a GABAA receptor agonist phenol derivative that has a novel structure and better efficacy, can effectively reduce side effects, and is safer for clinical use. Specifically disclosed are a compound as represented by the following formula (I), a stereoisomer and pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and an application of the compound or composition of the present invention in the central nervous field, thereby providing more and better choices for medicaments for inducing and/or maintaining anesthesia in animal or human bodies, facilitating sedation and hypnosis, and treating and/or preventing anxiety, nausea, vomiting, migraine, convulsion, epilepsy, neurodegenerative diseases, and central nervous system-related diseases.

##STR00001##

Provided is a GABAA receptor agonist phenol derivative that has a novel structure and better efficacy, can effectively reduce side effects, and is safer for clinical use. Specifically disclosed are a compound as represented by the following formula (I), a stereoisomer and pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and an application of the compound or composition of the present invention in the central nervous field, thereby providing more and better choices for medicaments for inducing and/or maintaining anesthesia in animal or human bodies, facilitating sedation and hypnosis, and treating and/or preventing anxiety, nausea, vomiting, migraine, convulsion, epilepsy, neurodegenerative diseases, and central nervous system-related diseases.

##STR00001##

A compound useful as a release agent, and a release agent, a curable composition, and a nanoimprint lithography resin material each containing the compound are provided. More specifically, a calixarene compound with a molecular structure represented by the following structural formula (1) and a composition containing the calixarene compound are provided.

##STR00001##

wherein R.sup.1 denotes a structural moiety with a perfluoroalkyl group, R.sup.2 denotes a hydrogen atom, a polar group, a polymerizable group, or a structural moiety with a polar group or a polymerizable group, R.sup.3 denotes a hydrogen atom, an aliphatic hydrocarbon group that may have a substituent, or an aryl group that may have a substituent, n denotes an integer in the range of 2 to 10, and * denotes a bonding point with an aromatic ring.

A compound useful as a release agent, and a release agent, a curable composition, and a nanoimprint lithography resin material each containing the compound are provided. More specifically, a calixarene compound with a molecular structure represented by the following structural formula (1) and a composition containing the calixarene compound are provided.

##STR00001##

wherein R.sup.1 denotes a structural moiety with a perfluoroalkyl group, R.sup.2 denotes a hydrogen atom, a polar group, a polymerizable group, or a structural moiety with a polar group or a polymerizable group, R.sup.3 denotes a hydrogen atom, an aliphatic hydrocarbon group that may have a substituent, or an aryl group that may have a substituent, n denotes an integer in the range of 2 to 10, and * denotes a bonding point with an aromatic ring.

Novel selective synthesis route to introduce primary alkyl groups on aromatic compounds is disclosed. The synthesis route is based on electrophilic aromatic substitutions of thionium ion species that are generated in-situ from aldehydes and thiols, affording benzyl sulfide that can be reduced with triethylsilane.